石藥(01093.HK)一度急回9%近乎回吐本月升幅 為最差藍籌
石藥(01093.HK)今早開市微升至17.14元後突掉頭向下,一度急跌9%至15.54元,跌穿10天線(16.2元)及20天線(15.85元),近乎全數回吐本月升幅。現時下挫逾8%報15.6元,暫為最差藍籌,成交達8.4億元,已顯著超越昨日(10日)全日成交額。
另外,中生製藥(01177.HK)亦緊隨其後,逆市跌逾3%報10.48元,為第二差表現藍籌。惟仍有醫藥股逆市造好,復星醫藥(02196.HK)微升0.2%報21.2元,國藥(01099.HK)升1.6%報25.95元,中國中藥(00570.HK)亦略升0.5%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.